Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum

被引:17
作者
Bowker, K. E. [1 ]
Garvey, M. I.
Noel, A. R.
Tomaselli, S. G.
MacGowan, A. P.
机构
[1] North Bristol NHS Trust, Bristol Ctr Antimicrobial Res & Evaluat, Bristol BS10 5NB, Avon, England
关键词
in vitro; S; pneumoniae; fluoroquinolones; RESPIRATORY-TRACT INFECTIONS; IN-VITRO; FLUOROQUINOLONE RESISTANCE; EFFLUX PUMPS; PHARMACODYNAMICS; CIPROFLOXACIN; SELECTION; MODEL; SUSCEPTIBILITY; GATIFLOXACIN;
D O I
10.1093/jac/dks537
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We aim to further define the impact of the mechanism of fluoroquinolone resistance and inoculum load on the pharmacodynamic effects of levofloxacin and moxifloxacin on Streptococcus pneumoniae. The antibacterial effects of and emergence of resistance (EoR) to moxifloxacin (400 mg once daily) or levofloxacin (750 mg once daily or 500 mg twice daily) were compared using five S. pneumoniae strains containing no known resistance mechanisms, efflux resistance mechanisms, a parC mutation or parC and gyrA mutations, at high (10(8) cfu/mL) and low (10(6) cfu/mL) inocula. An in vitro pharmacokinetic model was used and simulations were performed over 96 h. After drug exposure, isolates were tested for the presence of efflux pumps and mutations in the quinolone resistance-determining regions. A high inoculum diminished the antibacterial effect of moxifloxacin and levofloxacin. Levofloxacin at both dosages produced EoR with all strains. Levofloxacin regimens with AUC/MIC ratios 100 produced EoR. Moxifloxacin produced EoR with the parC strain only. Levofloxacin dosing regimens with low AUC/MIC ratios select for efflux pump overexpression, leading to fluoroquinolone resistance. Levofloxacin dosing may select for gyrA mutations, inducing moxifloxacin resistance. These data confirm that a fluoroquinolone AUC/MIC ratio of 100 is required for prevention of EoR.
引用
收藏
页码:1130 / 1138
页数:9
相关论文
共 23 条
[1]   Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[2]   Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models [J].
Andes, D ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1665-1670
[3]   Determination of minimum inhibitory concentrations [J].
Andrews, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 :5-16
[4]   Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations [J].
Avrain, Laetitia ;
Garvey, Mark ;
Mesaros, Narcisa ;
Glupczynski, Youri ;
Mingeot-Leclercq, Marie-Paule ;
Piddock, Laura J. V. ;
Tulkens, Paul M. ;
Vanhoof, Raymond ;
Van Bambeke, Francoise .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (05) :965-972
[5]   Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae:: Contributions of type II topoisomerase mutations and efflux to levels of resistance [J].
Bast, DJ ;
Low, DE ;
Duncan, CL ;
Kilburn, L ;
Mandell, LA ;
Davidson, RJ ;
de Azavedo, JCS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3049-3054
[6]   Gemifloxacin for the treatment of respiratory tract infections: In vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety [J].
Bhavnani, SM ;
Andes, DR .
PHARMACOTHERAPY, 2005, 25 (05) :717-740
[7]   Evidence for efflux pumps, other than PmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae [J].
Brenwald, NP ;
Appelbaum, P ;
Davies, T ;
Gill, MJ .
CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (02) :140-143
[8]   Activities of newer fluoroquinolones against ciprofloxacin resistant Streptococcus pneumoniae [J].
Coyle, EA ;
Kaatz, GW ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1654-1659
[9]   In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations [J].
De Vecchi, E. ;
Nicola, L. ;
Ossola, F. ;
Drago, L. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (04) :721-727
[10]   Overexpression of patA and patB, Which Encode ABC Transporters, Is Associated with Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae [J].
Garvey, Mark I. ;
Baylay, Alison J. ;
Wong, Ryan L. ;
Piddock, Laura J. V. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (01) :190-196